Which Biosimilars Will Payers Cover? Manufacturer Pedigree Will Be A Factor
This article was originally published in The Pink Sheet Daily
Large established firms will have an advantage in the competition for formulary position, payer survey finds.
You may also be interested in...
As Onyx Details Come Out, Amgen Turns To Biosimilars
Amgen is juggling both ends of its strategy, one focused on biosimilars and the other on new R&D-driven products. Further details have emerged about each, as Amgen tries to make the case it's a revenue growth story.
Biosimilar Remicade Will Pit Rising Cost Pressures Against Prescriber Caution
If approved in Europe this year, as expected, Celltrion/Hospira’s biosimilar infliximab will provide a compelling test of whether and how quickly budgetary pressures can override physician caution. It will also set the stage for the $70 billion worth of copycat antibodies in development.
Supreme Court Seems Ready To Uphold Ruling Against Amgen’s Anti-PCSK9 Antibody Patents
Justices question what Amgen’s invention covers in its dispute with Sanofi. They appear inclined to uphold Federal Circuit’s standard for enablement despite potential negative impact on genus claims.